Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $950
Portfolio Pulse from jenniferd'souza@benzinga.com
Oppenheimer analyst Hartaj Singh has maintained an 'Outperform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $900 to $950.
August 04, 2023 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' price target has been raised from $900 to $950 by Oppenheimer, maintaining an 'Outperform' rating.
The raised price target and maintained 'Outperform' rating by Oppenheimer indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100